Oral Sodium Clodronate for Nonmetastatic Prostate Cancer—Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)
J. Natl. Cancer Inst. Mason et al.
99: 765
Supplementary Data
Files in this Data Supplement:
- Supplementary Table 1 -
Death Categorization
- Supplementary Table 2 -
Subgroup Analyses
- Supplementary Fig. 1 -
Risk difference for symptomatic bone metastases or prostate cancer death (primary outcome measure). Curve showing the difference in absolute risk over time for the primary outcome measure of symptomatic bone metastases or death from prostate cancer, calculated using the Royston-Parmar method (31). From the smoothed curves, the differences at 2 years is –4% (95% confidence interval CI = –8% to 0%) in favor of placebo and at 5 years is –3% (95% CI = –10% to 4%) in favor of placebo.
- Supplementary Fig. 2 -
Risk difference for death from any cause (ONS). Curve showing the difference in absolute risk over time for death from any cause, calculated using the Royston-Parmar method (31). From the smoothed curves, the differences at 2 years is –2% (95% confidence interval CI = –4% to 0%) in favor of placebo and at 5 years is –2% (95% CI = –7% to 4%) in favor of placebo.
- Supplementary Fig. 3 -
Risk difference for prostate cancer death (ONS). Curve showing the difference in absolute risk over time for death from prostate cancer, calculated using the Royston-Parmar method (31). From the smoothed curves, the differences at 2 years is –1% (95% confidence interval CI = –4%, 2%) in favor of placebo and at 5 years is 0% (95% CI = –7% to 6%).
